Patrick Ruddock
About Patrick Ruddock
Patrick Ruddock's Role at AtomVie
Patrick Ruddock serves as the Director of Regulatory and Clinical at AtomVie. In this position, he is responsible for overseeing all regulatory and clinical research activities within the organization. Since taking up this role in 2022, Patrick has brought his extensive experience in regulatory affairs to the company, particularly focusing on regulatory compliance and clinical trials. His expertise covers various areas, including radiopharmaceuticals, biologics, and medical devices, critically ensuring that AtomVie adheres to industry standards and regulatory guidelines.
Patrick Ruddock's Career at CPDC
Patrick Ruddock began his career with CPDC, the parent company of AtomVie, in 2011. He joined as a Regulatory Affairs Associate and has since advanced within the organization. His role at CPDC involved managing chemical manufacturing and control (CMC) as well as clinical aspects of regulatory affairs. Over the years, Patrick has accumulated over 14 years of industry experience which has prepared him to take on a leadership role in regulatory and clinical spheres at AtomVie.
Patrick Ruddock's Educational Background
Patrick Ruddock holds a Master of Science degree in Microbiology from the University of Ottawa, providing a strong foundation in the biological sciences. Additionally, he obtained a post-graduate certificate in Regulatory Affairs from Humber College, equipping him with specialized knowledge and skills in regulatory practices. This educational background has been instrumental in his career, enabling him to navigate the complexities of regulatory requirements in the healthcare sector.
Experience in Regulatory Affairs
Patrick Ruddock has over 14 years' experience in regulatory affairs, specifically in the realms of chemical manufacturing, clinical trials, and regulatory compliance. His work has included regulatory activities for radiopharmaceuticals, biologics, and medical devices. Patrick’s comprehensive understanding of both the CMC and clinical regulatory landscapes has been instrumental in his ability to manage and lead regulatory and clinical research activities at AtomVie.